EP Patent

EP2289518A1 — Therapeutic agent for inflammatory bowel disease

Assigned to Nippon Shinyaku Co Ltd · Expires 2011-03-02 · 15y expired

What this patent protects

The main object of the present invention is to provide an agent for the treatment of inflammatory bowel diseases. The present invention relates to an agent for the treatment of inflammatory bowel diseases containing the heterocyclic derivative represented by the following g…

USPTO Abstract

The main object of the present invention is to provide an agent for the treatment of inflammatory bowel diseases. The present invention relates to an agent for the treatment of inflammatory bowel diseases containing the heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient; In the formula (1), and are the same or different and each represents an optionally substituted aryl; R 3 and R 4 are the same or different and each represents hydrogen atom or alkyl; R 5 represents hydrogen atom, alkyl or halogen atom; Y represents N or N→O; A represents NR 6 , and R 6 represents hydrogen atom, alkyl, etc.; D represents alkylene or alkenylene which is optionally substituted with hydroxy; E represents phenylene or a single bond; G represents O, S, etc.; and Q represents carboxy, alkoxycarbonyl, etc.

Drugs covered by this patent

Patent Metadata

Patent number
EP2289518A1
Jurisdiction
EP
Classification
Expires
2011-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Nippon Shinyaku Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.